Emily P. Thi

1.6k total citations
39 papers, 1.1k citations indexed

About

Emily P. Thi is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Emily P. Thi has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Epidemiology, 14 papers in Hepatology and 12 papers in Molecular Biology. Recurrent topics in Emily P. Thi's work include Hepatitis B Virus Studies (25 papers), Hepatitis C virus research (14 papers) and Liver Disease Diagnosis and Treatment (9 papers). Emily P. Thi is often cited by papers focused on Hepatitis B Virus Studies (25 papers), Hepatitis C virus research (14 papers) and Liver Disease Diagnosis and Treatment (9 papers). Emily P. Thi collaborates with scholars based in Canada, United States and Australia. Emily P. Thi's co-authors include Neil E. Reiner, Amy C. H. Lee, Joan B. Geisbert, Thomas W. Geisbert, Chad E. Mire, Krystle N. Agans, Karla A. Fenton, Peter J. Unrau, H. Alexander Ebhardt and Ming‐Bo Wang and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Emily P. Thi

39 papers receiving 1.1k citations

Peers

Emily P. Thi

EPIDE

IMMUN

Shih‐Tung Liu Taiwan

Fahad N. Almajhdi Saudi Arabia

Jamuna Vadivelu Malaysia

Minjoo Yeom South Korea

Yansong Sun China

Paola Flórez de Sessions Singapore

Heejoon Myung South Korea

Belén Borrego Spain

James A. Garnett United Kingdom

Abdul Razak Mariatulqabtiah Malaysia

Shih‐Tung Liu Taiwan

Emily P. Thi

395 ×1.1

360 ×1.1

219 ×0.8

EPIDE

139 ×0.8

106 ×0.8

IMMUN

Citations per year, relative to Emily P. Thi Emily P. Thi (= 1×) peers Shih‐Tung Liu

Countries citing papers authored by Emily P. Thi

Since Specialization

Citations

This map shows the geographic impact of Emily P. Thi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily P. Thi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily P. Thi more than expected).

Fields of papers citing papers by Emily P. Thi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily P. Thi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily P. Thi. The network helps show where Emily P. Thi may publish in the future.

Co-authorship network of co-authors of Emily P. Thi

This figure shows the co-authorship network connecting the top 25 collaborators of Emily P. Thi. A scholar is included among the top collaborators of Emily P. Thi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily P. Thi. Emily P. Thi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mesaros, Eugen F., Andrew G. Cole, Steven G. Kultgen, et al.. (2024). Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators. ACS Medicinal Chemistry Letters. 15(9). 1627–1634. 2 indexed citations

Cole, Andrew G., Steven G. Kultgen, Nagraj Mani, et al.. (2024). Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836. Journal of Medicinal Chemistry. 67(18). 16773–16795. 4 indexed citations

Lam, Angela M., Muhammad Sheraz, Fei Liu, et al.. (2024). Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161. Viruses. 16(3). 323–323. 5 indexed citations

Thi, Emily P., Xin Ye, Nicholas M. Snead, et al.. (2024). Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic. ACS Infectious Diseases. 10(10). 3640–3649. 6 indexed citations

Anderson, Mark, et al.. (2023). Measuring hepatitis B pgRNA stability using an updated automated HBV pgRNA assay with increased sensitivity. Hepatology Communications. 7(4). 7 indexed citations

Cole, Andrew G., Steven G. Kultgen, Nagraj Mani, et al.. (2023). Design, synthesis, and structure-activity relationship of a bicyclic HBV capsid assembly modulator chemotype leading to the identification of clinical candidate AB-506. Bioorganic & Medicinal Chemistry Letters. 94. 129456–129456. 4 indexed citations

Yuen, Man‐Fung, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.. (2022). Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B. Hepatology Communications. 6(12). 3457–3472. 17 indexed citations

Thi, Emily P., Andrew G. Cole, Seyma Ozturk, et al.. (2022). Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients. Journal of Hepatology. 77. S848–S848. 1 indexed citations

Paratala, Bhavna, Man‐Fung Yuen, Edward Gane, et al.. (2022). Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients. Journal of Hepatology. 77. S850–S850. 3 indexed citations

10.

Lam, Kieu, Xin Ye, A. D. Martin, et al.. (2021). Ligand conjugate SAR and enhanced delivery in NHP. Molecular Therapy. 29(10). 2910–2919. 8 indexed citations

11.

Thi, Emily P., Andrea Cuconati, Andrew S. Kondratowicz, et al.. (2018). ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. ACS Infectious Diseases. 5(5). 725–737. 46 indexed citations

12.

Ye, Xin, Chise Tateno, Emily P. Thi, et al.. (2018). Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model. ACS Infectious Diseases. 5(5). 738–749. 22 indexed citations

13.

Mire, Chad E., Joan B. Geisbert, Krystle N. Agans, et al.. (2016). Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. The Journal of Infectious Diseases. 214(suppl 3). S367–S374. 32 indexed citations

14.

Thi, Emily P., Amy C. H. Lee, Joan B. Geisbert, et al.. (2016). Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nature Microbiology. 1(10). 16142–16142. 43 indexed citations

15.

Thi, Emily P., Chad E. Mire, Amy C. H. Lee, et al.. (2015). Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 521(7552). 362–365. 190 indexed citations

16.

Thi, Emily P., Ulrike Lambertz, & Neil E. Reiner. (2012). Sleeping with the Enemy: How Intracellular Pathogens Cope with a Macrophage Lifestyle. PLoS Pathogens. 8(3). e1002551–e1002551. 74 indexed citations

17.

Thi, Emily P., Ulrike Lambertz, & Neil E. Reiner. (2012). Class IA Phosphatidylinositol 3-Kinase p110α Regulates Phagosome Maturation. PLoS ONE. 7(8). e43668–e43668. 8 indexed citations

18.

Martínez‐Gutiérrez, Fidel, Emily P. Thi, Judith M. Silverman, et al.. (2011). Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles. Nanomedicine Nanotechnology Biology and Medicine. 8(3). 328–336. 239 indexed citations

19.

Cooper, Dawn, et al.. (2007). Aedes Dronc: a novel ecdysone‐inducible caspase in the yellow fever mosquito, Aedes aegypti. Insect Molecular Biology. 16(5). 563–572. 21 indexed citations

20.

Cooper, Dawn, et al.. (2007). Characterization of Aedes Dredd: A novel initiator caspase from the yellow fever mosquito, Aedes aegypti. Insect Biochemistry and Molecular Biology. 37(6). 559–569. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact